Northwest Medical Laboratory Symposium
Virtual
Educational Sessions
Vendor Presentations

October 15 - 16, 2020
Get Ready to Attend Our First Virtual Northwest Medical Lab Symposium

The Virtual NWMLS will take place over two days. It is live, conducted via Zoom, and all registered attendees will be sent a link to join the meeting with separate links for each session. In addition to four educational sessions each day, we are also scheduling several Industry Partner Presentations.

**Your fee covers both days of the NWMLS.**
The live sessions will be recorded and available to registered attendees for 30 days after the meeting.

**Registration Deadline:** Tuesday, Oct 13, 2020

### NWMLS Program Grid

<table>
<thead>
<tr>
<th>Time</th>
<th>Thursday, Oct 15, 2020</th>
<th>Friday, Oct 16, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:00 am</td>
<td>Lab Safety in the Age of Novel Infectious Agents: How CLSI Can Help You</td>
<td>Mysterious Coagulation Results: Investigations and Solutions</td>
</tr>
<tr>
<td>9:30 - 10:15 am</td>
<td>Industry Partner Presentation</td>
<td>Industry Partner Presentation</td>
</tr>
<tr>
<td></td>
<td>Audit MicroControls</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td></td>
<td>Industry Partner Presentation</td>
<td>Helmer Scientific</td>
</tr>
<tr>
<td></td>
<td>Bio-Rad Laboratories</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:45 am</td>
<td>Current Drug Trends in Forensic Casework</td>
<td>Latent TB Testing: Improving Laboratory Efficiency</td>
</tr>
<tr>
<td>11:45 am - 12:30 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 1:30 pm</td>
<td>THC and CBD - Meet Your New Neighbors</td>
<td>Congenital CMV: Underdiagnosed and Underappreciated</td>
</tr>
<tr>
<td>2:00 - 2:45 pm</td>
<td>Industry Partner Presentation</td>
<td>Industry Partner Presentation</td>
</tr>
<tr>
<td></td>
<td>Quidel</td>
<td>WSLH Proficiency Testing</td>
</tr>
<tr>
<td></td>
<td>Industry Partner Presentation</td>
<td>Industry Partner Presentation</td>
</tr>
<tr>
<td></td>
<td>ARKRAY USA</td>
<td>Hettich Instruments</td>
</tr>
<tr>
<td></td>
<td>Industry Partner Presentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEDTOX Diagnostics</td>
<td></td>
</tr>
<tr>
<td>3:15 - 4:15 pm</td>
<td>The Effect of COVID 19 on Blood Donor Collections</td>
<td>SARSCoV2 / COVID19 Update: Have We Learned Any Lessons?</td>
</tr>
<tr>
<td>5:00 - 7:00 pm</td>
<td>Virtual Happy Hour</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Join your colleagues for fun and chat. Bring your own drinks and snacks</td>
<td></td>
</tr>
</tbody>
</table>
### Lab Safety in the Age of Novel Infectious Agents: How CLSI Can Help You

**- Luann Ochs, MS**  
**CLSI, WAYNE, PA**

In this session, we'll look at the latest requirements for laboratory safety. Then we'll look at the CLSI resources available for your laboratory to help you meet the requirements. We'll also look at some best practices for safety recommended by CLSI.

**Objectives:**
- Describe the US government requirements for laboratory safety.
- Outline lab safety best practices.
- Discuss the CLSI resources available to help meet the requirements.

**P.A.C.E. # 011-305-20**

### Current Drug Trends in Forensic Casework

**- Amy Miles, BS**  
**Wisconsin State Laboratory of Hygiene, Madison, WI**

This session will provide an overview of the current drug trends in drug-impaired driving and Medical Examiner casework. Several cases will be used to detail the analytical and legal challenges as well as various drugs’ effect on human performance.

- Describe the current drug trends in Medical Examiner and impaired drivers
- Describe basic drug impairment by a variety of categories
- Outline the difference between clinical and forensic testing

**P.A.C.E. # 011-302-20**

**Sponsor: Wisconsin State Laboratory of Hygiene**

### Company Presentations

**9:30 - 10:15 am**

Each company will give a 15 minute presentation about their current products or services.

- Audit MicroControls
- Bio-Rad Laboratories
- Abbott
**THC and CBD - Meet Your New Neighbors**

- **Amy Miles, BS**  
  Wisconsin State Laboratory of Hygiene, Madison, WI

THC and CBD have quickly become mainstream with the removal of hemp from Schedule I and the decriminalization of THC in many states. This session will cover the basics of THC and CBD, analytical challenges, and their effects on human performance. Case examples will be discussed.

Objectives:
- Discuss the basics of THC.
- Outline the difference between THC and CBD.
- Describe the effects of THC on human performance.

P.A.C.E. # 011-303-20

*Sponsor: Wisconsin State Laboratory of Hygiene*

---

**The Effect of COVID 19 on Blood Donor Collections**

- **Theresa Nester, MD**  
  Bloodworks Northwest
- **Kirsten Alcorn, MD**  
  Bloodworks Northwest

This session will describe the effect of COVID 19 on blood donor collections, including a discussion of Convalescent Plasma, how it is collected, data regarding efficacy, and changes to the blood donation criteria.

- Explain Convalescent Plasma and criteria for collection.
- Discuss data regarding Convalescent Plasma efficacy.
- List changes to blood donation criteria based on recent evidence of Classic and variant Creutzfeldt-Jakob disease.

P.A.C.E. # 011-304-20

*Sponsor: Bloodworks Northwest*

---

**Company Presentations**

2:00 - 3:00 pm

Each company will give a 15 minute presentation about their current products or services.

- **Quidel**
- **ARKRAY USA**
- **MEDTOX Diagnostics**

---

**Virtual Happy Hour**

5:00 - 7:00 pm

Come join us for fun, and talk with colleagues. Bring your own drinks and snacks.
Mysterious Coagulation Results: Investigations and Solutions

- Karen A Burns CLS MT (ASCP), Instrumentation Laboratory, Vancouver, WA

We have all experienced those unusual coagulation results in the laboratory. How do we investigate them? This case-based lecture reviews some of the common occurrences involving sample collection and processing and the effects on coagulation results. Discussion will revolve around the investigation of the spurious results and how to avoid them.

Objectives:
- Identify specimen collection and processing errors that can lead to erroneous coagulation results.
- Recognize incorrect coagulation results due to assay interferences and sensitivity.
- Describe the significance of clinical history in interpreting coagulation results.
- Describe the effect anticoagulants have on coagulation assay results.

Latent TB Testing: Improving Laboratory Efficiency

- Glen Hansen, PhD
  Hennepin County Medical Center

Individuals at high-risk for TB infection and disease progression require rapid, accurate testing. In the United States thirteen million individuals are believed to silently carry latent TB infection. Without treatment, they are at risk for developing active TB disease. The good news is that TB disease is preventable and curable. If TB infection is recognized early, doctors can provide effective preventive treatment. The CDC recommends Interferon-gamma Release Assay testing (IGRA) for the majority of the U.S. testing population. According to the CDC, IGRAs are preferred for TB testing in most risk group.

Those likely to be infected with TB are

1. Anyone with low or intermediate risk of disease progression.
2. Those for whom it has been decided that testing for latent TB infection is warranted.
3. IGRAs are also strongly recommended in those who are also BCG-vaccinated, or unlikely to return to have their TST read.

Objectives:
- Discuss LTBI testing landscape and pros and cons of the methods available.
- Discuss how automated IGRA testing can improve and simplify LTBI testing workflow.
- Review decision drivers, process, and impact of implementation of LIAISON QuantiFERON-TB Gold Plus for LTBI testing.

Company Presentations 9:30 - 10:15 am

Each company will give a 15 minute presentation about their current products or services.

Beckman Coulter
Helmer Scientific
Diasorin Molecular
Congenital CMV: Underdiagnosed and Underappreciated

- Sarah Elliott, PhD
  DiaSorin Molecular

Human cytomegalovirus (CMV) is one of the most common herpesviruses, infecting nearly half of the adult population in the US. While it is well established that CMV is responsible for a high level of morbidity and mortality in immunocompromised individuals, the awareness that CMV is also a leading cause of congenital infections worldwide is quite low. An estimated 1 in 200 infants is born with congenital CMV infection in the US, giving this virus the dubious distinction of causing more cases of congenital disease than the other 29 most commonly screened conditions combined. Though most infants born with congenital CMV infection will not have any complications, about 10% will experience a range of symptoms at birth. Up to 20% of those infants may die due to complications from the infection, and 40-60% of the survivors will develop severe long-term complications. In fact, congenital CMV is the most common non-genetic cause of childhood hearing loss. Early detection of congenital CMV infection is critical for timely clinical intervention, including treatment with antiviral medications, which may lessen the severity of the hearing and developmental impairments associated with this infection. This talk will focus on the epidemiology, disease manifestations, and diagnosis of congenital CMV infection.

Objectives:

- Describe the general biology of human herpesviruses and the viral life-cycle of CMV.
- Summarize the epidemiology, disease manifestations and treatment of congenital CMV infections.
- Identify the laboratory methods used to diagnose congenital CMV infections and the relevant guidelines associated with testing.

P.A.C.E. # 011-307-20

Sponsor: DiaSorin Molecular

Company Presentations
2:00 - 2:45 pm

Each company will give a 15 minute presentation about their current products or services.

WSLH Proficiency Testing
Hettich Instruments
SARSTEDT
Emerging and reemerging pathogens leading to a global pandemic is a complex issue driven by globalization and neglect for preparedness in health security. Obviously, we have reached a dangerous tipping point. The nature of this critical public health and healthcare problem has two primary components: 1) the emergence of diverse and novel pathogens, and 2) the alarming ability of these pathogens to be translocated and transmitted in a wide array of geographic and densely populated regions. The adaptation and survival of these dangerous pathogens is associated with ongoing and increasing natural selective pressure as it relates to human, animal, and environmental health settings. The primary drivers for this mounting trend of pathogens include, but is not limited to, changing patterns of pathogen epidemiology, emergence of drug-resistance genes, animal husbandry, antimicrobial use / stewardship, population mobility, increased rates of human urbanization, and the movement and ease of products and goods across global settings. Simply stated, emerging pathogens are incredibly versatile biological entities at adaptation to every natural (and unnatural) niche known to humankind. Understanding them is critical to curbing their ongoing global drift. I will address the emergence and spread of emerging pathogens from a medical laboratory, public health lens, including, and how this threat affects the ever-evolving relationship between hosts and pathogens.

Objectives:

- Provide an update on the current SARSCoV2 (COVID-19) pandemic.
- Discuss the factors associated with the globalization of infectious diseases, including historical and current examples of how select pathogens can evade antimicrobial treatments, and how this confers an evolutionary advantage to that pathogen.
- List and describe the effects of globalization in the spread of pathogens, particularly international travel and urbanization.
- Describe how proper public policy, medical intervention strategies, and development of novel therapies can be used to curtail the emergence of pathogens.
- Correlate the local and global issue of these pathogens through the lenses of globalization and public health.

P.A.C.E. # 011-308-20
# Registration Form

2020 Northwest Medical Laboratory Symposium  
October 15 - 16, 2020  
Virtual Meeting  

Online registration and credit card payment is available at  
www.asclswa.org/NWMLS.html  
or  
For mail registration send this form with a check.

First Name ____________________________________  
Last Name ____________________________________  

Address  
________________________________________________________________________________________  

City/State/Zip  
____________________________________________________________________________________  

Phone _______________________________________  

Institution  
________________________________________________________________________________________  

City/State  
________________________________________________________________________________________  

Email Address ___________________________________  

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
<th>Total Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASCLS/AMT Professional/Technical</strong></td>
<td>$40.00</td>
<td>$</td>
</tr>
<tr>
<td>ASCLS #</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AMT #</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-Member</strong></td>
<td>$56.00</td>
<td>$</td>
</tr>
<tr>
<td><strong>Student</strong></td>
<td>$10.00</td>
<td>$</td>
</tr>
<tr>
<td><strong>Total Fee</strong></td>
<td></td>
<td>$</td>
</tr>
</tbody>
</table>

---

Your fee covers both days of the NWMLS.

The live sessions will be recorded and available to registered attendees for 30 days after the meeting.

---

**To Register by Mail:**

Complete the registration form and mail the registration form and check payable to Northwest Medical Lab Symposium to:

2020 Northwest Medical Laboratory Symposium  
Brenda Kochis  
44 West 26th Avenue  
Spokane, WA 99203-1818  

If questions, contact Brenda Kochis:  
Email preferred: BrenKoch@comcast.net  
Phone (before 8 pm) 509-939-8445 (leave message).

---

**To Register Online:**

Go to www.asclswa.org/NWMLS.html. Click on “Online Registration” to go to the online form. Credit cards can be used to pay for registration.

---

**Registration Deadline: Tuesday, Oct 13, 2020**

This deadline is to allow us to provide the information for access to the Virtual NWMLS.